Rocket Pharma director granted RSUs and options
ROCKET PHARMACEUTALS, INC. director David P. Southwell reported equity awards, not open-market trades.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ROCKET PHARMACEUTALS, INC. director David P. Southwell reported equity awards, not open-market trades. He received 22,862 restricted stock units (RSUs) that convert one-for-one into common stock and will vest in full on June 18, 2027. He was also granted a stock option for 64,860 shares of common stock at an exercise price of $3.35 per share, which becomes fully vested and exercisable on June 18, 2027 and expires on June 18, 2036. Following these awards, he directly owns 54,522 shares of common stock and indirectly holds 113,124 shares through The David P. Southwell Irrevocable Trust dated April 14, 2024.
Insider Trade Summary
Grant/Award: 87,722 shares
Grant/Award
3 txns
Insider
SOUTHWELL DAVID P
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 64,860 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 22,862 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 64,860 contracts (Direct);
Common Stock — 54,522 shares (Direct);
Common Stock — 113,124 shares (Indirect, By The David P. Southwell Irrevocable Trust Dtd 04/14/2024)
Footnotes (2)
- F1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
- F2. This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
Key Figures
RSU grant size: 22,862 RSUs
Option shares granted: 64,860 shares
Option exercise price: $3.35 per share
+4 more
7 metrics
RSU grant size
22,862 RSUs
Restricted stock units vesting June 18, 2027
Option shares granted
64,860 shares
Stock option for Rocket Pharmaceuticals common stock
Option exercise price
$3.35 per share
Strike price for 64,860-share option
Option expiration
June 18, 2036
Expiration date of granted stock option
RSU vesting date
June 18, 2027
Full vesting date for 22,862 RSUs
Direct shares after awards
54,522 shares
Direct Rocket Pharmaceuticals holdings post-transaction
Indirect trust holdings
113,124 shares
Held by The David P. Southwell Irrevocable Trust
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), exercise price, irrevocable trust, +1 more
5 terms
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with 64,860 underlying shares of Common Stock."
exercise price financial
"conversion_or_exercise_price": "3.3500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
irrevocable trust financial
"By The David P. Southwell Irrevocable Trust Dtd 04/14/2024"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
vest financial
"The RSUs will vest in full on June 18, 2027."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did RCKT director David P. Southwell report?
David P. Southwell reported equity awards in Rocket Pharmaceuticals stock, not market trades. He received 22,862 RSUs and a stock option for 64,860 shares, both vesting in 2027 as part of his director compensation.
How many Rocket Pharmaceuticals (RCKT) RSUs were granted to David P. Southwell?
He received 22,862 restricted stock units that convert to Rocket Pharmaceuticals common stock on a one-for-one basis. These RSUs vest in full on June 18, 2027, aligning compensation with longer-term company performance and continued service.
What are the terms of David P. Southwell’s new stock option in RCKT?
He was granted a stock option for 64,860 shares of Rocket Pharmaceuticals common stock at an exercise price of $3.35 per share. The option fully vests on June 18, 2027 and expires on June 18, 2036, supporting long-term alignment.
When do David P. Southwell’s Rocket Pharmaceuticals RSUs and options vest?
Both equity awards have a single future vesting date. The 22,862 RSUs vest in full on June 18, 2027, and the option for 64,860 shares also becomes fully vested and exercisable on that same June 18, 2027 date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates